Pharmaceutical composition for preventing and treating cardiorenal syndrome and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of cardiorenal syndrome and composition, applied in the direction of drug combination, pharmaceutical formula, cardiovascular system diseases, etc.
Inactive Publication Date: 2021-06-18
QIANFOSHAN HOSPITAL OF SHANDONG
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
At present, the use of benzoyl neoaconitine, benzoyl aconitine, pachylic acid A, atractylodes lactone III, and paeonifloride glycosides is used for the prevention and treatment of targeted inflammation in heart-kidney intersection diseases. Drugs, not yet reported
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0045] Preparation of Capsules for Prevention and Treatment of Cardiorenal Syndrome:
[0046] Take 30g of benzoyl aconitine, 100g of benzoyl aconitine, 200g of pachylic acid A, 100g of atractylodes lactone III, 40g of paeonifloride glycoside, add appropriate amount of starch, mix well, pack into capsules, and make 1000 capsules , that is.
Embodiment 2
[0048] Preparation of dripping pills for preventing and treating cardiorenal syndrome:
[0049] Take 60 g of benzoyl neoaconitine, 50 g of benzoyl aconitine, 185 g of pachylic acid A, 140 g of atractylodes lactone III, 110 g of paeonifloride glycosides, and 500 g of polyethylene glycol, heat to melt, and mix well, Move it to the liquid reservoir of the dropping pill machine, keep it warm at 90°C, drop it into the cooled simethicone oil, and make 1000g of dropping pills.
Embodiment 3
[0051] Preparation of Injection for Prevention and Treatment of Cardiorenal Syndrome:
[0052] Take 66g of benzoyl neoaconitine, 30g of benzoyl aconitine, 170g of pachylic acid A, 140g of atractylodes lactone III, and 80g of paeonifloride glycoside, add 1800ml of water for injection, stir to dissolve, and use saturated sodium hydroxide Adjust the pH value of the solution to 7.0-7.5, add 10g of activated carbon for needles, add water for injection to 2000ml, mix well, boil for 30 minutes, refrigerate, filter, add water for injection to 5000ml, and use 0.45μm and 0.22μm microporous filters respectively Membrane filtration, sub-package, each 5ml, filled with nitrogen, sealed, steam sterilization for 30 minutes, that is, 1000 concentrated solution for injection.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides a pharmaceutical composition for preventing and treating cardiorenal syndrome. The pharmaceutical composition is prepared from 2.2-8.8 parts of benzoylmesaconine, 2.5 to 10.0 parts of benzoylhypacoitine, 5.2 to 20.8 parts of pachymic acid A, 4.4 to 17.6 parts of atractylenolide III and 3.8 to 15.2 parts of albiflorin. The titer of the pharmaceutical composition for preventing and treating cardiorenal syndrome can reach 93.02%. According to the pharmaceutical composition disclosed by the invention, the contents of the benzoylmesaconine and the benzoylhypacoitine are limited, so that toxic and side effects caused by the benzoylmesaconine and the benzoylhypacoitine on a human body are avoided, the pharmaceutical composition can be used trustingly, and the curative effect is enhanced; and finally, a foundation is laid for further developing a novel active ingredient composition preparation.
Description
technical field [0001] The invention belongs to the field of research and development of traditional Chinese medicines, and in particular relates to a pharmaceutical composition for preventing and treating cardiorenal syndrome and its application. Background technique [0002] With the aging trend of society and the increasing incidence of diabetes, the coexistence of heart and kidney dysfunction is becoming more and more common. Cardiac intersection diseases have become an interdisciplinary key and difficult problem. A large number of studies have confirmed that the heart and kidney are both important organs to maintain the body's circulatory homeostasis, and the functions of the heart and kidney can affect each other. Compared with a single disease, the damage to the heart and kidney functions reflected by it is not superimposed, but exceeds the body. The sum of the morbidity and mortality of single organ failure and its resulting serious events. Modern studies have found...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more